WT1-Related Wilms Tumor Syndromes Latest Advances

Find the Latest Research About WT1-Related Wilms Tumor Syndromes

  • Overview
  • Find a Doctor
  • Latest Advances
  • Clinical Trials
  • Treatments

Customize your search results with filters

Term Search
    You can select from the dropdown list OR enter your own terms to refine the search.

    Last Updated : 06/20/2022

    Save publications for later
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
    Found 12 publications

    Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.

    Condition: Acute Leukemia
    Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
    Treatment Used: Dendritic Cells Based Immunotherapy
    Number of Patients: 11
    Published: March 06, 2022
    View publication
    Summary: Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.

    A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

    Condition: WT1-Positive Tumors
    Journal: Scientific reports
    Treatment Used: WT2725 WT1-Derived Oligopeptide Vaccine
    Number of Patients: 44
    Published: November 17, 2021
    View publication
    Summary: A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies.

    Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

    Condition: Recurrent Ovarian Cancer
    Journal: Journal for immunotherapy of cancer
    Treatment Used: Autologous WT1-Sensitized T Cells
    Number of Patients: 12
    Published: August 26, 2021
    View publication
    Summary: Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.

    Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.

    Journal: International journal of molecular sciences
    Published: July 24, 2021
    View publication
    Summary: Every Beat You Take-The Wilms' Tumor Suppressor WT1 and the Heart.

    Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

    Condition: Acute Myeloid Leukemia (AML)
    Journal: Frontiers in immunology
    Treatment Used: Combination Therapy with PD-1 Blockade after Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
    Number of Patients: 1
    Published: April 19, 2021
    View publication
    Summary: Case Report: Combination Therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Fatal GVHD.

    Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.

    Journal: Blood cells, molecules & diseases
    Published: February 26, 2021
    View publication
    Summary: Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia.

    T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

    Condition: Acute Myeloid Leukemia
    Journal: Nature medicine
    Treatment Used: T-Cell Receptor Gene Therapy after Hematopoietic Stem Cell Transplantation
    Number of Patients: 12
    Published: June 26, 2019
    View publication
    Summary: T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant.

    Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.

    Condition: Head and Neck Cancer
    Journal: Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
    Treatment Used: Willms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination combined with Conventional Chemotherapy
    Number of Patients: 11
    Published: April 30, 2019
    View publication
    Summary: Phase I/II Pilot Study of Wilms' Tumor 1 Peptide-Pulsed Dendritic Cell Vaccination Combined With Conventional Chemotherapy in Patients With Head and Neck Cancer.

    A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

    Condition: Recurrent malignant glioma
    Journal: Cancer immunology, immunotherapy : CII
    Treatment Used: Cocktail vaccine of WT1 human leukocyte antigen class I and II peptides
    Number of Patients: 14
    Published: November 16, 2018
    View publication
    Summary: A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.

    Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.

    Condition: Breast, ovarian, gastric cancer
    Journal: Cancer immunology, immunotherapy : CII
    Treatment Used: Dendritic cells vaccination with Wilms' tumor protein 1 (WT1)
    Number of Patients: 10
    Published: October 12, 2018
    View publication
    Summary: Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.

    Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

    Condition: Lower-risk Myelodysplastic Syndromes
    Journal: Cancer science
    Treatment Used: five-day regimen of azacitidine
    Number of Patients: 51
    Published: July 15, 2018
    View publication
    Summary: Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

    Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

    Condition: Acute Myeloid Leukemia (AML)
    Journal: Blood advances
    Treatment Used: Multivalent WT1 Peptide Vaccine (Galinpepimut-S)
    Number of Patients: 22
    Published: February 02, 2018
    View publication
    Summary: Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
    Showing 1-12 of 12

    Last Updated : 06/20/2022

    Better Care. Faster.
    • How MediFind Works
    • Our Story
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Newsroom
    • Partnering With Us
    • Contact Us
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    By subscribing, I agree to MediFind's Terms & Conditions and Privacy Policy.

    • FAQ
    • Feedback
    • Advertising Policy
    • Privacy Policy
    • Terms & Conditions
    Follow Us On
    MediFindBetter Care. Faster.
    © 2022 All Rights Reserved.

    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.